P2.10. First-line (1L) Lorlatinib in Patients with ALK-Positive aNSCLC: Updated Network Meta-Analysis (NMA) and Review of Ten NMAs - PDF(Abstract)
Back to course
Pdf Summary
Asset Subtitle
Sai-Hong Ignatius Ou
Meta Tag
Speaker Sai-Hong Ignatius Ou
Topic Metastatic NSCLC: Targeted Therapy - FUSIONS
first-line treatment
advanced non-small cell lung cancer
tyrosine kinase inhibitors
network meta-analysis
progression-free survival
adverse event outcomes
brain metastases
CROWN trial
Powered By